The 
Retroviral integrase (IN)
ʈ catalyzes the integration of reversetranscribed viral DNA into the host genome in two steps called processing and joining (1) (2) (3) . These reactions are chemically similar, proceeding via nucleophilic attack on the DNA by a donor hydroxyl group (water or ribose 3Ј OH), activated by the catalytic site of the enzyme. In vitro, these reactions require only divalent cations and water as cofactors. The in vitro reactions are fastest with Mn 2ϩ as the metal cofactor, although Mg 2ϩ also can be used. Because of its greater abundance in living cells, Mg 2ϩ is assumed to be the cofactor in vivo. Previous structural studies using the catalytic core domain of avian sarcoma virus (ASV) IN showed the presence of one cation of Mn 2ϩ or Mg 2ϩ , or two cations of Zn 2ϩ in the active site (4, 5) .
Retroviral INs are Ϸ300 amino acids in length and comprised three domains. The N-terminal domain (residues 1 to Ϸ50) binds and is stabilized by Zn 2ϩ (6) (7) (8) . The C-terminal domain (residues Ϸ200-300) binds DNA in a sequenceindependent fashion (9) . The catalytic core domain (residues Ϸ50-200) contains the active site triad consisting of residues Asp-64, Asp-121, and Glu-157. This triad is essential for enzymatic activity and binds the required metal cofactors (4, 5) . The structures of the C-and N-terminal domains of HIV-1 IN were solved by nuclear magnetic resonance (10) (11) (12) , whereas the core domains of HIV IN and ASV IN were determined by x-ray crystallography (13, 14) . Currently, no structural information is available for multi-domain fragments of IN.
Through its role in integration, IN is essential for the retroviral life cycle. Thus, IN is well suited as a target for drug design, especially as no analogous host enzymes are known (15) . No structural data on the binding of inhibitors, or even divalent cations, to HIV-1 IN have been published. For this reason, ASV IN has become an important target for structural studies. Here, we present the first structure of an inhibitor, Y-3, complexed to the catalytic core of ASV IN. Crystallization of the ASV IN-Y-3 complex thus has implications for directed antiviral drug design.
MATERIALS AND METHODS

Preparation and Analysis of Inhibitors.
To identify new HIV-1 IN inhibitors, we tested many compounds that showed activity in the National Cancer Institute's (NCI) antiviral drug screen against CEM-infected cells (virally infected cell line designed for antiviral screening assays). Several aromatic sulfones, disulfides, sulfonates, and sulfonamides were shown to inhibit IN at low micromolar concentrations (reviewed in ref. 16 ). Starting from known inhibitors including caffeic acid phenethyl ester and an anthraquinone derivative (NSC115290) (17), we derived a putative three-point pharmacophore model that was used to screen the National Cancer Institute threedimensional database of Ϸ200,000 compounds (18) . Compounds Y-1, Y-2, and Y-3 were identified in that search. Compounds Y-1, 5-(acetylamino)naphthalene-2-sulfonic acid; Y-2, 5-acetylamino-8-aminonaphthalene-2-sulfonic acid; and Y-3, 4-acetylamino-5-hydroxynaphthalene-2,7-disulfonic acid were obtained from the NCI Chemical Repository through the Drug Synthesis and Chemistry Branch. Compound Y-4, 4-acetylamino-5-hydroxynaphthalene-2-sulfonic acid (monosodium salt) (M r ϭ 281) was synthesized for this study by conversion of 8-aminonaphthalene-1,6-disulfonic acid to 4-amino-5-hydroxynaphthalene-2-disulfonic (sodium salt), using a published procedure (19) . The product was acetylated using acetic anhydride in anhydrous pyridine. All of the four compounds used for these experiments are derivatives of naphthalene (Fig. 1 ). For simplicity, alpha (␣) refers to the The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked ''advertisement'' in accordance with 18 U.S.C. §1734 solely to indicate this fact. aromatic ring with substituents R1, R2, and R5, and beta (␤) refers to the ring with substituents R3 and R4.
HIV-1 and ASV IN Assays. The 3Ј-processing and 3Ј-endjoining reactions of HIV-1 IN were assayed as described (20) . IC 50 values were determined by plotting inhibitor concentration vs. percent inhibition and calculating the concentration that produced 50% inhibition. Disintegration reactions were performed as described above with an oligonucleotide (i.e., branched substrate) in which the U5 end was ''integrated'' into target DNA (21) .
The 3Ј-processing activity of full-length ASV IN (1-286) and the endonucleolytic activity of the isolated catalytic core of ASV IN (52-207) were assayed as described (22) image plate detector (Nonius, Delft, The Netherlands). For most data sets, the high resolution diffraction limit extended to Ϸ2.0 Å with good scaling statistics. All of the data sets were processed and scaled with the HKL suite of programs (23); see Table 1 for statistics. In all cases, for refinement and electron density (ED) map calculations, x-ray data within the resolution range 8.0 Å to the highest available [F Ͼ 2.0⅐(F)] were used. A subset of data (Ϸ10% of all reflections) was excluded from refinement and used for cross-validation with free R-factor (24) . One structure of ASV IN, Protein Data Bank code 1ASV, was used always as the starting model after solvent was removed. Rigid body refinement was done to compensate for small variations in unit cell parameters. Difference Fourier maps (F o -F c and 2F o -F c ) were calculated, and the structure was adjusted manually. Positional refinement, followed by refinement of isotropic B-factors for nonhydrogen atoms, was done for each model. Further refinement was done only in cases for which the difference ED maps indicated changes in the conformations of protein elements, the presence of inhibitor bound to IN, and͞or bound Mn 2ϩ cation. Amino acid side chains were adjusted to agree with the corresponding ED, solvent molecules were placed in sites distant from the inhibitor binding site, and metal cation included as appropriate. New ED maps were calculated after more refinement, providing clearer information about inhibitor binding (Fig. 3) . The inhibitor molecule and missing solvent molecules were modeled into the ED map followed by additional refinement. All refinement and ED map calculations were performed with the program X-PLOR (25) ; visual inspection and manual modifications used molecular graphics packages O (26) and CHAIN (27) . . In all cases, Y-3 inhibited the processing activity of full-length protein in a concentration-dependent manner (Fig. 2 A) . . A reproducible increase of catalytic activity was observed at Y-3 concentrations slightly lower than those that were inhibitory. The reason for this unexpected enhancement is unknown. In a separate experiment (not shown), we preincubated full-length and core proteins with either the inhibitor or the metal cofactor. No difference in the inhibitory activity was observed, suggesting that Y-3 and cations do not compete for the metal binding site. indices h ϭ (h, k, l) . The free R-factor (Rfree) is calculated for a random set of reflections (10%) excluded from the refinement.
RESULTS
Description of the Inhibitor Binding Site. Of the four compounds investigated in this study, only Y-3 could be detected unambiguously in the ED map (Fig. 3) . Based on the similarity of average temperature factors of the protein and inhibitor (Table 1) , the binding site appears to be highly occupied. This site, located close to the crystallographic twofold axis, is formed by several residues of ASV IN located in the direct vicinity of the active site but not part of it (Fig.  4) . The contacts between the R1 and R2 groups of Y-3 and the first IN monomer involve two oxygens of R1 within hydrogen bond distance of Arg-158 NH 2 (3.1 Å), Gln-62 NE2 (2.8 Å), Ala-154 N (3.3 Å), and Met-155 N (3.1 Å). The Arg-158 hydrogen bond is rather weak, as deduced from its length and the existence of two alternate side chain orientations. The carbonyl oxygen of R2 forms hydrogen bonds with Lys-119 NZ (3.4 Å) and Glu-62 NE2 (2.9 Å). The methyl group of R2 is located in a hydrophobic pocket formed by the side chain of Ile-60 and the methyl group from the symmetry-related Y-3 molecule.
The symmetry-related second IN monomer interacts primarily with the R3 and R4 groups of the inhibitor. These interactions are weaker comparatively and stereochemically less well defined. The R3 group is in close contact with the main chain atoms of residues Ile-146, Gln-151, and Gly-152; only the first, between the R3 oxygen and Ile-146 N, is close enough (2.9 Å) to contribute significantly to Y-3 binding. The hydroxyl group R4 interacts with Lys-119 NZ (2.9 Å) and with a structural water molecule stabilized by interactions with protein atoms. . Several changes were observed, especially at lower pH. The most striking difference between the two structures at low pH is the orientation of the side chain of Asp-64, the central active site residue. In the apoenzyme, the side chain of this residue is oriented toward the side chain of Asp-121; in the inhibitor complex, it points in the opposite direction and forms two hydrogen bonds with the side chain of Asn-160 (Fig. 5A) . In the absence of inhibitor, the interaction between the side chains of Asp-64 and Asp-121 is mediated by a water molecule. In the complex, a water molecule remains with Asp-121; however, an additional water molecule lies near the original position of Asp-64 OD1. At pH 7.5, the orientation of this side chain is identical in the complex and the native enzyme. The pH dependence of Asp-64 conformation is probably a direct consequence of changes in its protonation state.
Lys-119 also is affected by inhibitor binding (Fig. 5A ). In the apoenzyme, its side chain is directed toward the center of the enzyme, forming a hydrogen bond with Thr-120 O, with a high B-factor indicating extensive side chain mobility. In the complex, this side chain reorients, turning away from the enzyme's center and forming a direct hydrogen bond with the inhibitor. The B-factor for this side chain is Ϸ2 times lower in the complex than in the reference structure.
Residues 144-154 of ASV IN, highly conserved in different INs, form a flexible loop believed to be important in substrate binding (29) (30) (31) . In 1ASV, most of the loop residues have very high B-factor values; in the ASV IN Y-3 complex, we were unable to determine loop structure for residues 147-152. In modeling this region (for completeness only), atomic occupancies were assigned zero values. Loop residues 144-146, however, showed clear conformational differences between the complex and 1ASV (Fig. 5B ) with these three residues shifted toward the inhibitor molecule by up to 2.8 Å (for C ␣ of Ile-146). These changes also alter local solvent structure.
Another affected residue is Asn-122, which is separated from the inhibitor binding site by the flexible loop. The change in its conformation may be a direct consequence of shifting the flexible loop. The same may be true for Glu-157, whose side chain has an altered conformation and also interacts with the flexible loop. In the complex, Glu-157 OE2 points toward Asp-64 (Ϸ3.7 Å), whereas Glu-157 OE1 is in a position occupied by a water molecule in the apoenzyme. We identified two conformations of the Arg-158 side chain. One conformation resembles Arg-158 in the apoenzyme, whereas in the other it approaches and hydrogen bonds with the inhibitor molecule. , as a control. The position and occupancy of the Mn 2ϩ -binding site were identical to the previously described structure (4). Inhibitor binding was similarly unaffected by pH change and Mn 2ϩ binding, indicating both metal cation and inhibitor can bind simultaneously. This observation is consistent with our biochemical results, which showed that the order of metal cation and inhibitor addition does not affect inhibition. Additionally, residue conformations at pH 7.5 were the same with or without Mn 2ϩ . This experiment allowed us to look at the effects of pH͞ buffer in the absence of inhibitor. Several residues have different side chain conformations at pH 7.5 (Hepes buffer) vs. pH 5.6 (citrate buffer). Besides the previously noted conformational change of the Asp-64 side chain, Arg-158 and Asn-122 also showed altered side chain conformations. At pH 7.5, Arg-158 appears in a single conformation, similar to that in the apoenzyme. The conformation of Asn-122 also was different, but this residue also shows a significant increase of B-factor values at the higher pH.
Residues 144-146 and Lys-119 were unaffected by pH or metal binding, but in the presence of the inhibitor, their conformations were different than in the apoenzyme. This result suggests that the binding of Y-3 alters the conformation of the flexible loop and of residues interacting with this loop. It is possible Y-3 inhibits ASV IN by interfering with the dynamic properties of this highly conserved loop and thus disrupting the interaction of the loop with the substrate molecule (31) . 
CONCLUSIONS
This structure of an inhibitor of both HIV-1 IN and ASV IN, solved in a complex with the latter enzyme, is the first reported example of its kind. IN inhibitor assays are done in vitro using artificial substrates and may not reflect precisely in vivo potency (32, 33) . It is therefore desirable to have independent confirmation of inhibitor binding specificity. In the case of Y-3, observed in vitro potency is supported by structural data; the inhibitor binds specifically in close vicinity to the active site and to the predicted nucleic acid binding site (29-31, 34) . Conformations of active site residues are altered upon inhibitor binding. Specific changes, notably the rotation of the Asp-64 side chain, are pH specific and complex. Experiments are underway to clarify their potential role in inhibition. Although the influence of Y-3 binding on the conformation of the flexible loop is clear and may account for its inhibitory activity, full interpretation of its significance awaits more data on the mode of IN-substrate binding. Although the nature of inhibition cannot be fully established, some possibilities can be ruled out. For example, there is no interference with the binding of an essential divalent cation.
Comparison of the isolated catalytic core domains of HIV-1 IN (13, 35) and ASV IN (14) indicates that, as crystallized, only the conformation of the catalytic residues of the latter is compatible with metal binding. This result was puzzling given the overall homology of these enzymes, and the known ability of HIV-1 IN to bind cations in solution (20) . We now find that under some conditions of low pH, ASV IN adopts an inactive conformation incapable of binding cations (unpublished data). 
